Navigation Links
Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting
Date:10/2/2007

ate-to-severe vasomotor symptoms associated with menopause; and treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. When prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered.

Patients should be started at the lowest approved dose of 0.3 mg ENJUVIA daily. Subsequent dosage adjustment may be made based upon the individual patient response. This dose should be periodically reassessed by the healthcare provider.

The most common side effects in the clinical trials were headache, pain, nausea, and breast pain. In clinical trials, adverse events that occurred at a rate greater than or equal to 5% and greater than placebo, regardless of relationship to study drug, included: abdominal pain, accidental injury, breast pain, bronchitis, dizziness, dysmenorrhea, flatulence, flu syndrome, headache, nausea, pain, paresthesia, rhinitis, sinusitis, and vaginitis.

ENJUVIA tablets should not be used in individuals with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or history of cancer of the breast; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism or a history of these conditions; active or recent (e.g. within the past year) arterial thromboembolic disease (e.g. stroke, myocardial infarction); liver dysfunction or disease; hypersensitivity to its ingredients; or known or suspected pregnancy. There is no indication for ENJUVIA in pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy.

Women and healthcare providers who would like to learn more about ENJUVIA, including full prescribing information, should visit '/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Glaxo launches pills to help smokers quit in 7-12 weeks
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. Dr Reddy’s Laboratories launches Hyalosy
4. Serum Institute Launches New Tetanus-Diphtheria Vaccine
5. Scottish Health Minister Launches Organ Donor Plan
6. GlaxoSmithKline launches diabetes and cancer drugs
7. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
8. Pfizer Launches Viagra For Lung Disease In UK
9. PM Launches Healthcare Foundation For India
10. African Union Launches A Programme On Acceleration of HIV Prevention
11. Yale School of Medicine Launches Telemonitoring Of Heart Failure Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
(Date:12/25/2014)... December 25, 2014 AngelWeddingDress.com tries its ... the online realm. Today, the business has introduced its ... site-wide prom dress promotion. , The new prom outfits ... and every dress lover. They are specially designed for ... prom dresses should visit its website before Jan. ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Residents ... Retirement Community, recently showed their generous spirit by ... the Catawba County Parenting Network- Grandparents Raising Grandchildren ... children gathered around the largest Christmas tree on ... presents purchased by residents of the Abernethy Village ...
(Date:12/25/2014)... 2014 Parker & Sons, Inc. an ... and affordable quality regarding heating, cooling and plumbing services ... 2014 by the “Queen of Clean” for impressive contractor ... impressive reputation over the years for providing outstanding quality ... of contractor services for both homeowners and businesses. Linda ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3
... very subtle change in the genetic constitution is what ... with it is unraveled, then health care can be ... share the same genetic code, how those genes express ... in developing medicines and dietary advice. According to a ...
... commonly advocated in menopausal woman. However taking this hormone ... and recently anxiety has been expressed. ,In a ... such a cancer developing in woman on HRT is low ... ,A team from New South Wales Breast Cancer Institute looked ...
... Nebraska, was slated for a slow but sure death, weighing in ... or even turn over in bed. , ,Deuel is now ... than 200 kg after undergoing an operation that is becoming increasingly ... opera singer, Deborah Voigt, also lost 50 kg after she underwent ...
... when drinking was considered to be forbidden. It has now ... new research has found that drinking is not all that ... to have better verbal skills, memory and speed of thinking ... drinkers not only performed the best but also seemed to ...
... recent research that is published in the latest issue ... not prevent infections in the elderly population. ,At ... mineral deficiency, which can lead to poor immunity and ... older people in the UK take nutritional supplements, but ...
... hair may be far more effective treatment of head ... single blind randomized controlled trial for comparing the Bug ... head lice in United Kingdom. , ,Fine combing ... over the counter chemical treatments for eliminating head lice, ...
Cached Medicine News:Health News:Learning Just How Different We Are 2Health News:Risk of Breast Cancer Overestimated with Hormone Replacement Therapy(HRT) Treatment 2Health News:Obesity better handled with gastric bypass surgery 2Health News:Yet Another Reason To Celebrate Drinking 2Health News:Combing Hair More Effective Than OTC Medicine For Head Lice 2
(Date:12/22/2014)... 2014 NxStage Medical, Inc. (NASDAQ: ... products, announced today that the U.S. Food and ... to perform hemodialysis overnight while the patient is ... NxStage,s® System One is the first and only ... indication. Home nocturnal hemodialysis is ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Therapeutics, Inc. today,announced completion of a Phase ... kappa opioid agonist, CR845, under development for ... drug candidate was safe and,well-tolerated after intravenous ... expected to be associated with clinical analgesic ...
... CyberKnife System at Oklahoma ... CyberKnife Center, ... global leader in the field of radiosurgery,announced today that the first ... was recently,installed at the Oklahoma CyberKnife, LLC in Tulsa, OK. The ...
Cached Medicine Technology:Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845 2New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 2New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 3New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 4
... a rapid, real-time thermal cycler used for ... automating much of the testing process, and ... is the fastest, easiest to use, and ... The SmartCycler delivers highly accurate and consistent ...
Inquire...
Chemically Resistant Sealing Mat for 384ch, Square Well Available Sterile...
96-well Silicone Compression Mat, Bulk...
Medicine Products: